CoChat

Genetics and Clinical Destiny: Improving Care in Hypertrophic Cardiomyopathy

Open access
Ho, Carolyn Y. · 2010 · Circulation
Cited by 140

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

T he greatest opportunity afforded by discovering the genetic basis of human heart disease is accurate prediction and prevention of illness.Hypertrophic cardiomyopathy (HCM) provides a paradigm to fulfill this opportunity.Human genetics research has identified many gene mutations that result in cardiac hypertrophy, of which HCM is the most common and well-characterized.Sarcomere gene mutations in HCM result in left ventricular hypertrophy (LVH), myocardial fibrosis and disarray, diastolic dysfunction, and increased risk for arrhythmias, sudden death, and heart failure.Making the clinical diagnosis of HCM currently hinges on identifying unexplained hypertrophy, but LVH is a sign of established disease only.This finding cannot identify at-risk mutation carriers and cannot discriminate HCM from other forms of cardiac hypertrophy, either genetic or acquired. Response by Landstrom on p 2440In contrast, gene-based diagnosis is not constrained in this manner.Defining the mutation that causes LVH in an individual provides an accurate diagnosis for that patient and, therefore, considerable information about their prognosis.Moreover, unlike clinical diagnosis which only identifies overt disease, genetic diagnosis can also identify patients at risk for developing disease.There are certainly many challenges to realizing the full potential of genetics, but such information provides unprecedented promise.Continued efforts to refine and clinically implement genetic testing in HCM will bring important payoffs in the future, and will serve as a model for other genetic cardiovascular diseases.By identifying at-risk individuals prior to clinical diagnosis, characterizing disease pathogenesis, and fostering development of novel therapies to delay or prevent phenotypic expression, genetic discoveries will improve the lives of our patients with HCM. Genetics of HCMThe familial, autosomal-dominant nature of HCM has long been recognized, but the precise genetic etiology was discovered through genome-wide linkage studies in the 1980s.This seminal work identified pathogenic mutations in genes encoding contractile proteins and established the paradigm that HCM is a disease of the sarcomere.1,2 Over the past 20 years, more than 900 individual mutations have been identified, the majority (Ϸ75% to 80%) involving cardiac ␤-myosin heavy chain (MYH7) and cardiac myosin binding protein C (MYBPC3).Other sarcomere genes, including cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), ␣-tropomyosin (TPM1), the myosin light chains (MYL2, MYL3) and actin (ACTC) have also been established as causing HCM.Genetic testing for HCM was initially available only in research laboratories and performed primarily to further basic understanding of disease.Clinical genetic testing can now be obtained through a variety of commercial laboratories, making diagnostic use feasible.Current testing is based on a candidate-gene approach, typically analyzing the 8 sarcomere genes most commonly implicated in HCM, listed above, and a small number of genes associated with metabolic/storage cardiomyopathies that may mimic HCM, including PRKAG2, LAMP2, and GLA, as discussed below.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.110.978924

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Ho, C. Y.
Venue
Circulation
Published
2010-12-07
Volume
122
Issue
23
Pages
2430-2440
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1971259806
Cited by
140
References
5
FWCI
9.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.